What adjuvant therapy would you recommend for a premenopausal woman with low ER+/PR+ (1-10%) HER2- pT1cN0 metaplastic breast cancer?

Does the low ER+ or metaplastic histology affect your recommendations?

Answer from: Medical Oncologist at Academic Institution

The rarity of the metaplastic subtype of breast cancer makes it difficult to provide an evidence-based answer regarding what is the "best" adjuvant treatment. About 70% of metaplastic tumors are TNBC and ER-low is a small subset of the remaining 20% with an ER+ epithelial component. In general, some...

Comments

Medical Oncologist at NYU Winthrop Hospital
Excellent review, Dr. @Soliman.

Answer from: Medical Oncologist at Academic Institution

While I agree with Dr. @Soliman that I would recommend that this patient receive adjuvant chemotherapy and that I would treat her as having triple-negative disease, as I would a patient with an ER-low invasive ductal carcinoma, I would definitely treat her with weekly paclitaxel and carboplatin, as ...

Comments

Medical Oncologist at START Center for Cancer Care
Metaplastic TNBC has poor response to anthracyclin...

Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
Just to clarify, you would treat this as TNBC but ...

Medical Oncologist at Warren Alpert Medical School of Brown University
Yes, I would not administer immunotherapy with or ...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
There isn't a large amount of data on pembrolizuma...

Please select the option that best describes you:

What adjuvant therapy would you recommend for a premenopausal woman with low ER+/PR+ (1-10%) HER2- pT1cN0 metaplastic breast cancer?

Related Questions